ReNeuron Group plc Senior business development appointment
12 July 2019 - 4:00PM
RNS Non-Regulatory
TIDMRENE
ReNeuron Group plc
12 July 2019
12 July 2019 AIM: RENE
RNS REACH
ReNeuron Group plc
("ReNeuron" or the "Company")
Senior business development appointment
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces the appointment
of Nicholas Adams in the newly created role of VP Business
Development & Alliance Management.
His appointment reflects the continued clinical progress at the
Company, the current and anticipated level of interest from
potential licensing partners in the Company's programmes and the
importance of the ongoing management of licensing and other
agreements once signed.
Nick has considerable experience leading a range of
international deal types including in- and out-licensing,
divestments, spin-outs and mergers and acquisitions. He has a BSc
in biology and law qualifications, with 30 years' experience in the
pharmaceutical and biotechnology industries. His early career was
in clinical development, at companies including Ciba-Geigy (now
Novartis), Cephalon and Eisai, after which he moved into business
development. Nick was Vice-President, Business Development at
Antisoma plc, where more than US$160m was raised through licensing
deals and divestments. More recently, he has served as Chief
Business Officer at Clavis Pharma ASA and then Redx Pharma plc.
Olav Hellebø, Chief Executive Officer of ReNeuron,
commented:
"I'm delighted to welcome Nick Adams to ReNeuron's executive
team. He will strengthen our business development capabilities and
also be a dedicated resource for managing current and future
licensing agreements. As highlighted in recent announcements,
business development has become an increasingly important aspect of
the Company's activities as we pursue discussions with commercial
third parties regarding potential collaboration and/or
out-licensing deals across our programmes."
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK) +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Argot Partners (US) +1 212 600 1902
Stephanie Marks, Claudia Styslinger
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
N+1 Singer +44 (0) 20 7496 3000
Aubrey Powell, James Moat, Iqra Amin
(Joint Broker)
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead clinical-stage candidates are in
development for the blindness-causing disease, retinitis
pigmentosa, and for disability as a result of stroke. ReNeuron is
also advancing its proprietary exosome technology platform as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action. ReNeuron's shares are traded on the
London AIM market under the symbol RENE.L. For further information
visit www.reneuron.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAKMGMNKMZGLZM
(END) Dow Jones Newswires
July 12, 2019 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024